CLINICAL_TRIALS
trial_result
· 2022-06-06
Clinical Trial Update: An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum [Phase 2]
Summary
Phase 2 open-label proof-of-concept study evaluating ixekizumab for pyoderma gangrenosum has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ohio State University | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: COMPLETED | Results posted: 2022-06-06